Stammdaten
Vincerx Pharma, Inc., a clinical-stage biopharmaceutical company, researches and develops therapies to address unmet medical needs for the treatment of cancer in the United States. Its lead product candidate is VIP152, a cyclin-dependent kinase-9 inhibitor for treating patients with advanced cancer. The company's preclinical stage product candidates include VIP217, an oral PTEFb/CDK9 inhibitor; VIP236, a small molecule drug conjugate to treat solid tumors; and VIP943 and VIP924 for the treatment of hematologic malignancies. Vincerx Pharma, Inc. was founded in 2019 is headquartered in Palo Alto, California.
Unternehmen & Branche
| Name | Vincerx Pharma, Inc. |
|---|---|
| Ticker | VINC |
| CIK | 0001796129 |
| Boerse | US |
| Sektor | Healthcare |
| Industrie | Biotechnology |
Wertpapier & Kennzahlen
| CUSIP | – |
|---|---|
| ISIN | – |
| Typ | Common Stock |
| Marktkapitalisierung | 66.475 USD |
| Beta | 1,47 |
| Dividendenrendite | 0,00 % |
Externe Quellen: SEC EDGAR » · FMP-Profil » · Yahoo Finance »
Finanzkennzahlen (SEC XBRL)
| Periode | Filing | Umsatz | Nettoergebnis | EPS | Aktiva | Eigenkapital |
|---|---|---|---|---|---|---|
| 2025-03-31 | 10-Q | -5,000,000 | -1.40 | 4,686,000 | 2,066,000 | |
| 2024-12-31 | 10-K | -30,074,000 | -15.85 | 8,005,000 | 2,724,000 | |
| 2024-09-30 | 10-Q | -7,843,000 | -0.17 | 14,947,000 | 9,108,000 | |
| 2024-06-30 | 10-Q | -1,808,000 | -0.05 | 21,527,000 | 15,448,000 | |
| 2024-03-31 | 10-Q | -12,429,000 | -11.46 | 11,083,000 | -622,000 | |
| 2023-12-31 | 10-K | -40,157,000 | -37.72 | 18,217,000 | 11,222,000 | |
| 2023-09-30 | 10-Q | -9,007,000 | -0.42 | 26,276,000 | 15,741,000 | |
| 2023-06-30 | 10-Q | -11,550,000 | -0.54 | 35,275,000 | 24,136,000 | |
| 2023-03-31 | 10-Q | -14,650,000 | -0.69 | 47,448,000 | 34,466,000 | |
| 2022-12-31 | 10-K | -62,984,000 | -3.00 | 59,286,000 | 47,668,000 | |
| 2022-09-30 | 10-Q | -16,879,000 | -0.80 | 72,376,000 | 59,707,000 | |
| 2022-06-30 | 10-Q | -18,421,000 | -0.88 | 87,744,000 | 74,363,000 | |
| 2022-03-31 | 10-Q | -16,424,000 | -0.79 | 103,881,000 | 89,170,000 | |
| 2021-12-31 | 10-K | -39,306,000 | -2.29 | 117,676,000 | 100,321,000 | |
| 2021-09-30 | 10-Q | -24,524,000 | -1.39 | 129,425,000 | 100,626,000 | |
| 2021-06-30 | 10-Q | -2,034,000 | -0.12 | 91,137,000 | 71,595,000 | |
| 2021-03-31 | 10-Q | -6,276,000 | 58,000,000 | 25,553,000 | ||
| 2020-12-31 | 10-K | -16,620,000 | 63,192,000 | 25,379,000 | ||
| 2020-09-30 | 10-Q | -307,000 | 66,334,714 | -384,000 | ||
| 2020-06-30 | 10-Q | -33,000 | 66,482,977 | -80,000 |
Fondsaktivität (Vorquartalsvergleich)
Keine Fondsdaten für dieses Unternehmen vorhanden.
Insider-Transaktionen (12 Monate)
Keine Insider-Käufe/Verkäufe in den letzten 12 Monaten.
Top-Fondshalter
Keine Fondsdaten zu dieser Aktie vorhanden.